MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

Summary

Open-label, dose-confirmation and cohort expansion, multicenter, Phase Ib/II study to assess the anti-tumor activity and safety of MEN1611 in combination with cetuximab for the treatment of participants with phosphatidylinositol 3-kinase, catalytic, alpha polypeptide gene (PIK3CA)-mutated metastatic colorectal cancer.

Timeline

Start

2020-07-20

Primary completion

2024-01-12

Completion

2024-02-27

Drugs

Indications